The CEO's total reported pay of approximately $20.1 million in 2025 is notably lower than his $40 million in 2024, reflecting a normalization after large one-time spin-off grants. The pay structure is strongly performance-oriented — 92% of CEO target pay is variable and tied to preset financial and market goals — and the company added relative total shareholder return as a metric for long-term stock awards in direct response to shareholder feedback. Prior-year say-on-pay support was approximately 85%, well above the 70% concern threshold, and the company demonstrated clear responsiveness to investor input by strengthening stock ownership requirements and adding TSR-linked performance conditions. Variable pay was earned against genuine financial hurdles (constant currency revenue, adjusted operating income, and free cash flow), all of which were achieved above target in Solventum's first full year as a standalone public company, and the 3-year peer-group TSR gap of -7.6 percentage points is well within the 20-percentage-point threshold that would trigger a pay-for-performance concern under our policy.

The proxy filing does not disclose PwC's tenure as Solventum's auditor, nor does it break out specific audit fee and non-audit fee dollar amounts in the extracted text provided; per policy, when tenure cannot be confirmed the tenure trigger does not fire, and without fee data the non-audit fee ratio test cannot be applied. Solventum only became an independent public company in April 2024, suggesting PwC's tenure as auditor of the standalone entity is very short. PwC is a Big 4 firm fully appropriate for an $11 billion market-cap healthcare company, and the audit committee — which includes two designated financial experts — has affirmed PwC's independence. A FOR vote is warranted with a minor note that tenure and fee disclosures should be clearer in future proxy filings.